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Background: Systemic immunomodulatory treatment is ac-
tively recommended in the treatment for moderate to severe 
atopic dermatitis (AD) patients. However, consensus criteria 
for the classification of AD severity or treatment refractori-
ness have not been established yet. Objective: To establish 
consensus criteria on the definition of severity classification 
and treatment refractoriness of AD to provide a basis for 
proper treatment strategy. Methods: The Korean Atopic 
Dermatitis Association (KADA) comprised a task force team 
to establish a definition of moderate to severe AD. A draft of 
definition of moderate to severe AD was made on the basis 
of evidence. The recommendation was confirmed by KADA 
members through a web-based survey.  Results: KADA ap-
proved that AD with 16≤eczema area and severity index 
(EASI)＜23 should be basically defined as moderate AD 
whereas AD with EASI score ≥23 should be considered as 
severe AD. They agreed that it would be reasonable to raise 
the severity level if patient’s daytime or nighttime pruritus nu-
merical rating scale is equal to or higher than 7 (≥7) or der-
matology life quality index score exceeds 10. AD patients 
who do not reach EASI 50 after appropriate treatment for 
three months should be considered as a non-responder. 
Patients with recurrence (EASI ≥16) within three months af-
ter cessation of treatment should be considered as a recurrent 
AD. Conclusion: KADA built a consensus of definition of 
moderate and severe AD and treatment-refractoriness. These 
guidelines are expected to help physicians determine proper 
treatment options in need. (Ann Dermatol 31(6) 654∼661, 
2019)
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INTRODUCTION
Patients with atopic dermatitis (AD) exhibit a wide range 
of severity spectrum. Many publications classify the se-
verity of AD as mild, moderate, and severe. However, the 
criteria for the classification differ according to different 
studies. A broad consensus has not been established yet1-5.
Although a variety of instruments have been introduced to 
evaluate the severity of AD, they have relative advantages 
and disadvantages4. In a systematic review of sixteen in-
struments utilized for AD severity assessment, Schmitt et 
al.6 have concluded that eczema area and severity index 
(EASI) and the SCOring Atopic Dermatitis (SCORAD) are 
the best tools for measuring clinical sign of AD based on 
its validation, responsiveness, and inter-observer reliability. 
SCORAD has advantages in its responsiveness, inter-ob-
server reliability, and interpretability6. However, it has un-
clear intra-observer reliability which is its disadvantage. 
EASI is relatively simple compared to SCORAD and quick 
assessment is possible. It has a scoring system that meas-
ures lesions at multiple body parts and evaluates only ob-
jective symptoms6. Various countries have adopted differ-
ent AD severity assessment tools. In order to reflect ob-
jective symptoms of AD, the European guideline used 
SCORAD, the Italian guideline used EASI, the United States 
guideline and Japan guideline used body surface area and 
previous Korean guideline adopted both SCORAD and 
EASI7-11.
Subjective symptoms of AD patients may not necessarily 
be proportional to objective severities of AD. Thus, assess-
ments of subjective symptoms of itching, sleep disturb-
ance, and quality of life (QoL) are needed to reflect cor-
rect AD severity12. In particular, the EASI cannot reflect 
greater social problems resulting from lesions on exposed 
areas including head, face, neck, and hands. 
Various pruritus scales and dermatology life quality index 
(DLQI) can specifically assess itching and QoL, respect-
ively13-17. For measuring the severity of pruritus, visual an-
alogue scale (VAS), numerical rating scale (NRS), and ver-
bal rating scale have been reported to show high correla-
tions in chronic pruritus18,19. Patients tend to have higher 
itch scores in NRS than in VAS. The core outcome instru-
ments that reflect the QoL are DLQI, QoL index for AD, 
and Skindex. Among them, DLQI is primarily recom-
mended since it records the highest voting score as an in-
dicator of core outcome measurement20. 
It is necessary to determine how to use these objective 
and subjective indices in combination for the assessment 
of overall disease severity. However, methods of optimal 
severity assessment in clinical practice or cutoffs for se-
verity classifications vary from country to country. 
Some patients with AD need systemic treatment to control 
their symptoms. However, they may show varied respons-
es to treatment. Given the long-term nature of the disease, 
the possibility of adverse effects, and high medical costs, it 
is necessary to determine the degree of therapeutic re-
sponse which is regarded as clinically meaningful. In addi-
tion, such information is necessary to determine whether 
treatment should be continued10,21,22. In addition, most pa-
tients with moderate to severe AD experience worsening 
of symptoms once they stop treatment for AD. However, 
there is no consensus on meaningful recurrence to justify 
more aggressive and long-term treatment. For patients who 
do not respond to conventional therapies or experience 
recurrence, new therapeutic options should be considered 
and an evaluation system should be established.
To provide a basis for establishing appropriate treatment 
strategies for patients with AD, the objective of this study 
was to build a consensus on severity classification and 
treatment refractoriness of AD to be used by all physicians 
treating AD.
MATERIALS AND METHODS
The Korean Atopic Dermatitis Association (KADA) organi-
zed a task force team to establish definitions for moderate 
AD, severe AD, treatment-refractory AD, and recurrent 
AD. The task force team consisted of five dermatologists 
who were selected based on their clinical experience and 
academic achievements related to AD. Members of the 
task force team conducted extensive literature review on 
severity assessment and classification criteria of AD. They 
set up a draft on definition of each type of AD based on 
evidence collected. Some essential questions based on 
clinical experience were also developed and surveyed to 
recommend them as expert opinions. A total of 18 ques-
tions regarding definitions of moderate, severe, non-res-
ponder, and recurrent AD were developed and asked 
about their agreement (Table 1). To define each type of 
AD, both objective assessment by physicians and patients’ 
subjective symptoms were considered. 
Objective assessments
The EASI assesses erythema, edema, excoriation, and li-
chenification signs in four body sites (head and neck, 
trunk, upper extremity, and lower extremity). It is rela-
tively less time-consuming than SCORAD index. The 
SCORAD index is graded as follows: mild AD, SCORAD 
＜25; moderate AD, 25≤SCORAD＜50; and severe AD, 
SCORAD ≥503,4. The EASI describes AD severity as fol-
lows: mild, EASI score ＜16; moderate, 16≤EASI score
＜23; and severe, EASI score ≥232,4. The corresponding 
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Table 1. Consensus Expert Recommendations by KADA and agreement rate 
No. Recommendations Agreement (%)
1 EASI score is suitable for use in routine clinical practice for objective assessment of AD severity and monitoring. 97.3
2 Moderate AD is basically defined as an AD with 16≤EASI score＜23. 97.3
3 Severe AD is basically defined as an AD with EASI score ≥23. 89.2
4 To assess AD severity once before treatment is proper enough to reflect patients’ AD severity in moderate 
to severe AD patients.
100
5 AD with EASI score ＜16, but with lesions on the face, neck, hands, foot or genitalia is defined as moderate AD. 64.3
6 AD with 16≤EASI score＜23, but with lesions on the face, neck, hands, foot or genitalia is defined as severe AD. 64.9
7 To use NRS is recommended for itching scale of AD. 100
8 AD with EASI score ＜16, but with daytime or night time NRS ≥7 is defined as moderate AD. 81.1
9 AD with 16≤EASI score＜23, but with daytime or night time NRS ≥7 is defined as severe AD. 78.4
10 DLQI is recommended as a tool to assess the quality of life in AD patients. 100
11 AD with EASI score ＜16, but with DLQI ＞10 is defined as moderate AD. 73
12 AD with 16≤EASI score＜23, but with DLQI ＞10 is defined as severe AD. 73
13 To check DLQI is indicated only in patients with EASI score ＜23 and itching NRS ＜7 before treatment. 85.3
14 AD with allergic or non-allergic comorbidities or complications (i.e., asthma, cataract, depression) that need 
systemic treatment should be considered as severe AD.
62.2
KADA: The Korean Atopic Dermatitis Association, EASI: eczema area and severity index, AD: atopic dermatitis, NRS: numerical rating
scale, DLQI: dermatology life quality index.
Table 2. Questionnaire of dermatology life quality index (DLQI)
1. How itchy, sore, painful or stinging has your skin been?
2. How embarrassed or self-conscious have you been because of your skin?
3. How much has your skin interfered with you going shopping or looking after your home or garden?
4. How much has your skin influenced the clothes you wear? 
5. How much has your skin affected any social or leisure activities?
6. How much has your skin made it difficult for you to do any sport?
7. Has your skin prevented you from working or studying?
8. How much has your skin created problems with your partner or any of your close friends or relatives? 
9. How much has your skin caused any sexual difficulties?
10. How much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time?
score between EASI and SCORAD index is well validated 
in several literatures4. EASI of 16 corresponds to SCORAD 
index of 25 and EASI of 23 corresponds to SCORAD index 
of 502. 
In this study, we selected EASI for assessing the severity of 
AD in Korea based on the fact that EASI could be made 
without duplicating other subjective assessment systems 
such as VAS for itching, sleep disturbance, and QoL of 
AD. Whether EASI should be adopted to assess and mon-
itor AD severity in routine clinical practice, which score of 
EASI is proper to define moderate to severe AD, and when 
would be a proper time to assess EASI are addressed in 
this study. 
Subjective assessments
Pruritus is the chief complaint of AD patients and the key 
component to decide the direction of AD treatment. The 
task force team suggested NRS to assess pruritus in AD for 
its convenience to use. Patients rated intensity of itch from 
0 to 10 (0: no itch; mild pruritus: 1≤NRS≤3; moderate 
pruritus: 4≤NRS≤6; severe pruritus: 7≤NRS≤9; 10: 
worst imaginable itch)18.
DLQI is a validated tool to assess the QoL of patients with 
several skin diseases. DLQI comprises of ten questions in 
a relatively simple manner (Table 2). Ten questions each is 
scored 0 (no impact) to 3 (worst impact) on their symp-
toms and feelings, daily activities, leisure, work and school, 
personal relationships, and treatment. According to total 
DLQI, the following is considered: no effect: 0 to 1; mini-
mal effect: 2 to 5; moderate effect: 6 to 10; large effect: 11 
to 20; extremely large effect: 21 to 3020. The task force 
team suggested the use of DLQI to assess QoL in AD.
Standards as to what extent of decreased QoL will be judged 
as moderate or severe AD and what improved DLQI or 
minimum DLQI score should be regarded as appropriate 
level of therapeutic effect and treatment refractoriness are 
asked. In the measurement of severity of itching and de-
creased QoL in AD, participants in our study discussed 
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Table 3. Definition of moderate and severe AD
Moderate AD is defined as an AD with EASI score ≥16, or with EASI score ＜16 but at least one of the following conditions: 
a. Daytime or nighttime Itch with NRS score ≥7 
b. DLQI ＞10
Severe AD is defined as an AD with EASI score ≥23, or with 16≤EASI score＜23 but at least one of the following conditions: 
a. Daytime or nighttime Itch with NRS score ≥7 
b. DLQI ＞10 
AD: atopic dermatitis, EASI: eczema area and severity index, NRS: numerical rating scale, DLQI: dermatology life quality index.
whether to use a single, static, or serial analysis and when 
it would be appropriate to check improvement of each 
subjective symptom scale. 
Voting and consensus 
Consensus of the definition was confirmed by members of 
the KADA through two rounds of web-based question-
naire survey in modified Delphi manner11. A total of 41 of 
55 members participated in the first round of voting. They 
were asked whether they agreed with each statement or 
not. The task force team discussed results of the first round 
of voting and revised statements for the second round of 
voting, in which all voters were informed of the pro-
portion of agreement in the first round of voting. Thirty 
seven out of 55 members participated in the second vote. 
Consensus was defined as more than 70% agreement.
RESULTS 
Moderate and severe AD
Korean AD expert panel members came to an agreement 
about the definition of disease severity of AD. Details of 
the agreement are shown as follows. The agreement rate 
was settled by the final round of votes (Table 1).
1. Korean AD experts agreed to adopt the EASI to assess 
and monitor AD severity in routine clinical practice.
2. Our committee members agreed that moderate AD should 
be basically defined as an AD with 16≤EASI score＜23.
3. KADA members agreed that severe AD should be basi-
cally defined as an AD with EASI ≥23. 
4. AD lesions wax and wane. However, because most pa-
tients with moderate to severe AD tend to be persis-
tent in their lesions, Korean AD experts agreed that 
single static assessment of the EASI score before treat-
ment could properly reflect patients’ AD severity in 
moderate to severe AD patients.
5. The EASI score has a limitation to reflect the severity 
of several exposed areas such as hand, foot, and geni-
talia because it gives weight to the extent of certain 
areas. These lesion locations are directly related to so-
cial and functional impairment and low QoL. Thus, 
they should be separately assessed23,24. Large number 
of committee members agreed that AD with EASI 
score ＜16 but with lesions on the face, neck, hands, 
foot, or genitalia is defined as severe AD, although 
this was not included in the consensus criteria. These 
locations are very frequently affected in AD. The pres-
ence of lesions only in these locations did not seem to 
be enough to upstage the disease severity. Because 
there has been no validated assessment tool that re-
flects disease severity in these specific area so far. 
Thus, more validated tools to assess AD severity in 
critically QoL-related areas needs to be developed in 
the future.  
6. Consistently, the questionnaire that AD with 16≤EASI 
score＜23 but with lesions on face, neck, hands, foot, 
or genitalia should be defined as severe AD failed to 
reach an agreement.
7. Korean AD experts agreed that pruritus scale should 
be included for assessment of AD severity and that 
pruritus NRS should be adopted as a pruritus scale. 
8. KADA committee reached an agreement that AD with 
EASI＜16 but with severe pruritus (daytime or night-
time NRS≥7) should be considered as moderate AD 
and that such patients should be actively engaged in 
systemic immunomodulatory treatment. 
9. In the same respect, they agreed that AD with 16≤
EASI score＜23, but with daytime or night time NRS 
＞7 should be defined as severe AD.
10. Korean AD experts reached a consensus that DLQI 
should be recommended as a tool to assess QoL of 
patients with AD.
11. KADA agreed that patients with DLQI ＞10 should be 
considered as at least moderate AD even if EASI score 
was less than 16. 
12. They also agreed that AD with DLQI ＞10 should be 
considered as severe AD even if EASI score was be-
tween 16 and 23. 
13. It is not necessary to check DLQI in all typical moder-
ate to severe AD patients. DLQI should be checked in 
patients with EASI score ＜16 and itching NRS ≤7. 
However, for those with low QoL, other therapeutic 
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Table 5. Definition of treatment-refractory AD and recurrent AD
Treatment refractory AD is defined as an AD who failed to reach to EASI50 or at least one of the following conditions after 
3 months of appropriate treatment:
a. Daytime or nighttime Itch with NRS score ≥4 
b. DLQI ≥6
Recurrent AD is defined as an AD who has developed at least moderate severity of AD lesions within 3 months after cessation 
of appropriate treatment.
AD: atopic dermatitis, EASI: eczema area and severity index, NRS: numerical rating scale, DLQI: dermatology life quality index.
Table 4. Consensus Expert Recommendations on treatment-refractory and recurrent AD
Recommendations Agreement (%)
Treatment-refractory AD is defined as an AD who failed to reach to EASI50 after 3 months of appropriate treatment. 94.1
If pruritus NRS scales does not reach below NRS 4 after 3 months of appropriate treatment are defined as 
treatment-refractory AD patients.
70.6
If DLQI score does not decrease below DLQI 6 after 3 months of appropriate treatment are defined as 
treatment-refractory AD patients.
70.6
Recurrent AD is defined as an AD who developed at least moderate severity of AD lesions within 3 months after 
cessation of appropriate treatment.
94.1
AD: atopic dermatitis, EASI: eczema area and severity index, NRS: numerical rating scale, DLQI: dermatology life quality index.
options should be considered to improve their life 
quality. For AD with 16≤EASI score＜23 and itching 
NRS ≤7, but with low QoL, DLQI also should be 
checked. Of all participants, 85.3% agreed that single 
static measurement for DLQI before treatment would 
be optimal for defining moderate to severe AD.
14. AD severity usually increases as they have more comor-
bidity such as asthma. Patients with ocular problem 
cannot use proper amount of topical steroid although 
they might have severer clinical manifestation. Psycho-
logic comorbidities such as depression can decrease 
treatment compliance25. Obsessive behavior can ag-
gravate AD severity by vicious scratching cycle26. 
However, Korean AD experts failed to reach a con-
sensus on whether AD patients with allergic or non-al-
lergic comorbidities or complications that need sys-
temic treatment should be considered as severe AD. 
The definition of moderate and severe AD were made 
on the basis of the agreement above and described in 
Table 3.
Treatment-refractory AD and recurrent AD
Some AD patients are not categorized into moderate or se-
vere AD according to its definition, but they are treat-
ment-refractory. Korean AD experts have reached a con-
sensus that the definition of refractory or recurrent AD 
should leave room for patients to choose new treatment 
options. Of Korean AD experts, 97.3% and 81.1% agreed 
that definitions would be needed for non-responder and 
recurrent AD, respectively. Of all participants, 73.5% agreed 
that treatment refractoriness should be determined by not 
only EASI, but also relieving pruritus and QoL. In the same 
viewpoint, we adopted NRS and DLQI improvement as a 
tool for measuring treatment responsiveness. The follow-
ing consensus recommendations and definition were ach-
ieved (Table 4, 5).
1. Refractory AD should be defined for patients with treat-
ment refractoriness and patients who have not reached 
EASI 50 after three months of appropriate treatment 
are defined as treatment-refractory AD patients. 
2. If pruritus NRS scales do not reach below NRS ＜4 af-
ter three months of appropriate treatment, such pa-
tients should be defined as treatment-refractory AD 
patients.
3. If DLQI score does not decrease to be below 6 after 
three months of appropriate treatment, patients should 
be defined as treatment-refractory AD patients.
4. If patients with AD responded well to treatment, but 
developed at least moderate severity of AD lesions 
within three months after cessation of systemic or top-
ical immunomodulatory treatment, such patients should 
be defined as recurrent AD patients. 
DISCUSSION
AD is increasingly being recognized as a systemic disease 
rather than a localized skin disease. Although systematic 
treatment is necessary for moderate to severe AD patients 
who do not respond to local therapies or who experience 
recurrence, an established consensus guidelines or evalua-
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tion system to decide moderated and severe AD is still de-
bated upon diverse national guidelines7-9,11,27-29. Our study 
showed that a consensus could be made in defining mod-
erate AD (EASI score between 16 and 23) and severe AD 
(EASI score over 23). Besides EASI, itching and sleep dis-
turbance with NRS ≥7 obtained an agreement rate of 
78.4% to 81.1% while DLQI ＞10 obtained an agreement 
rate of 73% to upgrade the severity of AD. Such adjust-
ments in the guidelines are consistent with current trends 
which advocate that the severity of AD should be decided 
by comprehensive evaluation of objective skin assess-
ment, subjective symptoms, long-term control, relieve im-
pairments of QoL, and functional inconveniences due to 
the disease. In the United States, a steering committee of 
AD experts including dermatologists, allergists, and a pa-
tient advocacy group representative recommended to as-
sess the involvement of highly visible areas or those im-
portant for function (e.g., neck, face, genitals, palms, 
and/or soles) and QoL of the patient when evaluating the 
severity29. Recently, the European guidelines defined re-
current AD as having a grade of ‘moderate’ and a persis-
tent AD as ‘severe’9. This reflects how these guidelines not 
only consider the severity and area of skin lesions, but al-
so the recurrence or persistence of the disease in assessing 
their severity. Likewise, the Italian guideline recommends 
that even if the EASI score is less than 16, patient with skin 
lesions in one’s face, hands, genital area, or who experi-
ence itching and sleep disturbance with a VAS score over 
7 should be considered to have a moderate to severe 
AD10. However, our committee did not reach a consensus 
about the involvement of important location in exposed or 
functional areas. It is assumed that this is because there is 
no established standard for assessing the severity of the ex-
posed site or genitalia which is highly controversial.
Associations with allergic and non-allergic comorbidities 
are being increasingly reported in moderate to severe AD. 
Murao et al.30 have suggested that the severity of AD 
should be measured by adding scores based on complica-
tions of each patient. Similarly, the Singapore Guideline 
recommends that AD patients with psychological dysfunc-
tion should be treated as severe AD28. The Canadian 
guideline recommends early recognition and management 
of ocular comorbidities to prevent long-term sequelae and 
disability. Psychosomatic disease such as anxiety and de-
pression can be an important comorbidity of moderate to 
severe adult AD31. The European guideline recommends 
psychosomatic counseling for patients having over moder-
ate severity and those who are unresponsive to treatment9. 
However, the extent or severity of complications or co-
morbidities to be included is not specified, making it diffi-
cult to apply it to the real world. In our committee, 62.2% 
of respondents agreed that the severity of AD should be 
upgraded in the presence of complications or comorbid-
ities. This relatively low agreement suggests that each 
complication and comorbidity should be individually ana-
lyzed depending on the kind of complications and co-
morbidities as well as the severity in the future. 
The definition or criteria of non-responsiveness to treat-
ment remains unclear or controversial. Nonetheless, recent 
studies have proposed that non-responsiveness to treat-
ment, despite appropriate dose and duration of and adher-
ence to a therapeutic agent, may be defined by 1 or more 
of the following: inadequate clinical improvement, failure 
to achieve stable long-term disease control, presence of 
ongoing impairment (e.g., pruritus, pain, loss of sleep, and 
poor QoL) while on treatment, unacceptable adverse events 
or poor tolerability experienced with the treatment10,29. A 
high unmet need remains for novel definition or classi-
fication of treatment-refractory and recurrent or persistent 
AD. 
According to recent literature in the Italian clinical prac-
tice, a patient with AD is considered a non-responder to 
conventional systemic immunomodulatory therapies-cy-
closporine, methotrexate, and azathioprine or photother-
apy when he/she has not achieved an improvement of the 
considered severity indices of at least 50%, although the 
duration until the severity reaches EASI50 may vary de-
pending on treatment10. In psoriasis guideline, drug re-
placement is recommended when DLQI score is over 5 
even after sufficient treatment32. 
We thought that following up EASI50 at post-treatment 3 
months would be sufficient to expect responsiveness to 
treatment regardless of treatment types. According to our 
committee’s agreement that the definition of non-responder 
should include indicators of improvement of subjective 
symptoms of patients, we propose the following: 1) If AD 
patients will not reach to EASI50 after appropriate treat-
ment for 3 months, they are considered as treatment-re-
fractory AD patients; 2) If pruritus NRS scale does not 
reach below NRS4 or DLQI score does not decrease be-
low DLQI 6 after 3 months of appropriate treatment, pa-
tients should be defined as treatment-refractory AD pa-
tients.
We also suggest that in the case of recurrence over moder-
ate severity occurring within 3 months after cessation of 
systemic or topical treatment, these patients are consid-
ered as recurrent AD patients. Some patients may respond 
well to conventional systemic immunomodulatory treat-
ment. However, they can easily relapse with moderate se-
verity after discontinuation of treatment. Thus, recurrent 
AD patients are warranted to get more aggressive treat-
ment or longer period of treatment. However, safety issue 
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of long-term use of conventional systemic immunomo-
dulatory treatment still remains. If someone AD patients 
responded well, but had frequent relapse with significant 
severity, other treatment options should be considered for 
such patients to prevent possible adverse effects and im-
prove patients’ QoL. Consistently, Italian guideline sug-
gests that in the case of recurrence within 1 month after 
treatment discontinuation with a clinically significant in-
crease of severity index, a treatment change should be 
considered. In the case of worsening AD occurring within 
3 months after treatment discontinuation, a different ther-
apeutic option may be considered10. However, there is in-
sufficient level of information to define treatment refract-
ory AD and recurrent AD. The current definition of treat-
ment refractoriness in AD could be updated based on evi-
dence gained in the future. Our study limit is that these 
guidelines were developed by dermatologist group, not 
multidisciplinary. 
We suggested guidelines for classification of severity of 
AD and treatment refractoriness that are easy to apply by 
clinicians. Korean AD experts reached a consensus of defi-
nitions for moderate and severe AD with EASI scoring sys-
tem basically. These definitions could be modified by pru-
ritus scale and life quality index. When judging treatment 
refractoriness, both objective and subjective improvement 
should be considered together. Treatment strategy should 
be decided by considering long-term control and adverse 
effects. Patients with moderate to severe AD, treatment re-
fractory AD, or recurrent AD should be treated with prop-
er options to prevent further AD-related complications.
Moderate to severe AD patients struggle in their daily ac-
tivities due to low QoL as well as high medical cost24,33. 
We expect that the current definition of moderate to se-
vere AD and treatment refractoriness could be utilized as 
standard diagnostic criteria in Korea so that physicians 
could get some help in determining which patients need 
treatment step-up or replacement. 
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